Navigation Links
Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
Date:8/25/2011

nths and is used as a marker to determine the efficacy of glucose-lowering therapies.

"Linagliptin is primarily excreted unmetabolized via bile and gut, meaning no dose adjustment is needed in adult patients with kidney or liver impairment," said Prof. Anthony Barnett, professor of medicine and clinical director of the Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK. "This means that linagliptin is available at only one dose."

The approval of linagliptin in Europe was based on a clinical trial program which involved approximately 6,000 adults with type 2 diabetes. Included in the program were placebo-controlled studies evaluating linagliptin as monotherapy(4) and in combination with the commonly prescribed oral antihyperglycemic medications metformin and/or sulfonylurea.(2,5-6) In two monotherapy studies, linagliptin showed a statistically significant mean difference in A1C from placebo of -0.6 to -0.7 percent.(3-4) In patients who were not adequately controlled on metformin or metformin plus sulfonylurea, the addition of linagliptin also resulted in a statistically significant mean difference in A1C from placebo of -0.6 percent.(2,5) The incidence of hypoglycemia was similar to placebo and weight did not change significantly from baseline.(2,5)

In the pooled analysis of the placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo was similar to that seen with linagliptin (53.8 percent versus 55.0 percent).

The most frequently reported adverse reaction was hypoglycemia observed with the triple combination of linagliptin plus metformin plus sulfonylurea.

"The EU approval of linagliptin marks another major regulatory milestone for the Boehringer Ingelheim and Lilly alliance in diabetes," said Enrique Conterno, president of Lilly Diabetes. "Linagliptin can be an important treatment option for adults living with type 2 diabetes."

Wha
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
2. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
3. Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 Mylan Inc. (Nasdaq: MYL ) ... announced refinancing of its existing secured credit facility. The ... upsized from the originally planned $2.25 billion and comprises ... billion Term Loan A facility. The proceeds were used ...
... CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 University ... School of Medicine and Lentigen Corporation announced today the ... LG631 gene therapy for the protection of hematopoietic stem ... with Temodar.   Approximately 17,000 Americans are ...
Cached Medicine Technology:Mylan Successfully Upsizes and Completes Refinancing of Credit Facility 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... 2014 Fresh off their respective performances in ... meet on September 5th at Sun Life Stadium in an ... some of the brightest stars in the world of football ... will be treated to some of the best talent in ... as the third best team in the world according to ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... Demand Response Management Systems is a ... reducing the imbalance between energy supply and demand. With ... rolled out (due to increasing pressure on the grid) ... in controlling residential appliances and thermostats for load reduction. ... American region, and with government mandates and benefits for ...
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
Breaking Medicine News(10 mins):Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
... , SEATTLE, June 24 Lightspeed Design, Inc. announces ... software for state-of-the-art capture and playback of HD 3D ... hundreds of professional clients in corporate, entertainment, medical and ... into the new DepthQ(R) family of stereoscopic software -- ...
... , Pig jaw workshop gives attendees hands-on experience , ... RIEMSER , a leading manufacturer of bone tissue regeneration ... grafting workshop to be held in Chicago Friday, July 24th ... step-by-step instructions in site preservation, information on bone grafting materials ...
... doubt on notion of moms, unconditional love , ... likely than men to look away from less-than-cute babies, ... a mother,s unconditional love. , The findings might reflect ... healthy offspring, suggest the researchers, from Harvard-affiliated McLean Hospital ...
... OPEN NEXT SPRING IN HOUSTON METROPOLITAN AREA ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and ... a funding agreement with a national lender for the development ... metropolitan area. Funding for Trinity Terrace , an ...
... of Phosphatidylserine-Targeting Antibodies to Image Solid Tumors and Other Malignancies ... Showing Utility of PS-Targeting Antibodies for the Molecular Imaging of ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent ...
... Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use ... a New Report from AMR and Decision Resources , ... /PRNewswire/ -- Arlington Medical Resources (AMR) and ... oral formulation is a leading drug attribute that surveyed ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 2Health News:Women More Likely Than Men to Reject Unattractive Babies 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fourth Senior Living Facility 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 4Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: